Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Neoplasms 7Leukemia, Myeloid, Acute 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Neoplasm Metastasis 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, B-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Colonic Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1

Interventions

Carboplatin 339Cisplatin 238Paclitaxel 203Radiotherapy 194Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 140Erlotinib Hydrochloride 107Etoposide 98Magnetic Resonance Spectroscopy 92Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 71durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49Irinotecan 42atezolizumab 41Topotecan 39Radiation 39Biopsy 39Cyclophosphamide 38Standard of Care 37Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × ALT-803 × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡